Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of the IMMray PanCan-d Test in High-Risk Individuals Undergoing Pancreatic Surveillance: Pragmatic Data and Lessons Learned.

JCO precision oncology - 1 Sept 2023

Katona Bryson W, Worthington Christine, Clay Daniel, Cincotta Hannah, Ahmad Nuzhat A, Ginsberg Gregory G, Kochman Michael L, Brand Randall E

Abstract excerpt

PURPOSE: An effective blood-based test for pancreatic cancer (PC) screening has remained elusive. The IMMray PanCan-d is the first commercially available blood-based test specifically designed for early detection of PC; however, outcomes from its use in clinical practice have not been reported. METHODS: We performed a blinded spike-in study of 100 individuals who had an IMMray PanCan-d test, including 94...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Pancreatic Neoplasms

Source

Identifiers

PMID: 37883920
DOI: 10.1200/PO.23.00445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of the IMMray PanCan-d Test in High-Risk Individuals Undergoing Pancreatic Surveillance: Pragmatic Data and Lessons Learned.PMID 37883920Read ↗

Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.Semantic proximity Read ↗

Genomic testing for pancreatic cancer in clinical practice as real-world evidenceSemantic proximity Read ↗

Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort.Semantic proximity Read ↗

Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.Semantic proximity Read ↗

Performance of a multi-target, multi-cancer early detection (MCED) blood test in a prospectively collected cohortSemantic proximity Read ↗

Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data from the NORPACT-2 study.Semantic proximity Read ↗

Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoringSemantic proximity Read ↗

The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.Semantic proximity Read ↗

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNASemantic proximity Read ↗

Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learningSemantic proximity Read ↗

Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.Semantic proximity Read ↗

Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.